This information is intended for use by health professionals

  This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. Name of the medicinal product

Supemtek solution for injection in pre-filled syringe

Quadrivalent Influenza Vaccine (recombinant, prepared in cell culture)

2. Qualitative and quantitative composition

One dose (0.5 mL) contains:

Influenza virus haemagglutinin (HA) proteins, of the following strains*:

A/Wisconsin/588/2019 (H1N1) - like strain

(A/Wisconsin/588/2019)……………………………………………………

45 micrograms HA

A/Cambodia/e0826360/2020 (H3N2) - like strain

(A/Tasmania/503/2020)………………………………………………………

45 micrograms HA

B/Washington/02/2019 - like strain

(B/Washington/02/2019) ……………………………………………………

45 micrograms HA

B/Phuket/3073/2013 - like strain

(B/Phuket/3073/2013) ……………………………………………………

45 micrograms HA

* produced by recombinant DNA technology using a baculovirus expression system in a continuous insect cell line that is derived from Sf9 cells of the fall armyworm, Spodoptera frugiperda.

This vaccine complies with the World Health Organization (WHO) recommendation (Northern Hemisphere) and EU recommendation for the 2021/2022 season.

Supemtek may contain traces of octylphenol ethoxylate.

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Solution for injection in pre-filled syringe (injection).

Clear and colourless solution.

4. Clinical particulars
4.1 Therapeutic indications

Supemtek is indicated for active immunization for the prevention of influenza disease in adults.

Supemtek should be used in accordance with official recommendations.

4.2 Posology and method of administration

Posology:

One dose of 0.5 mL.

Paediatric population

Safety and efficacy of Supemtek have not yet been established in individuals below 18 years of age.

Method of administration:

For intramuscular injection only. The preferred site is in the deltoid muscle.

The vaccine must not be injected intravascularly and must not be mixed with other vaccines in the same syringe.

For instructions on the handling of the vaccine before administration, see section 6.6.

4.3 Contraindications

Hypersensitivity to the active substances, to any of the excipients listed in section 6.1 or to any trace residuals such as octylphenol ethoxylate.

4.4 Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Hypersensitivity

Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.

Intercurrent illness

Vaccination should be postponed in patients with acute febrile illness until the fever is resolved.

Immunodeficiency

Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient to prevent influenza.

Thrombocytopenia and coagulation disorders

As with all injectable vaccines, Supemtek must be administered with caution to individuals with thrombocytopaenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects.

Syncope

Syncope can occur following or even before any vaccination as a psychogenic response to the needle injection.This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. Procedures should be in place to prevent falling and injury and to manage syncope.

Protection

As with any vaccine, vaccination with Supemtek may not protect all vaccinees.

Sodium content

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say is essentially “sodium free”.

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed, nor data to assess the concomitant administration of Supemtek with other vaccines.

If Supemtek is to be given at the same time as another injectable vaccine, the vaccines should always be administered at different injection sites.

4.6 Fertility, pregnancy and lactation

Pregnancy

There is a limited amount of data from the use of Supemtek in pregnant women.

One animal study performed with trivalent recombinant influenza vaccine did not indicate direct or indirect harmful effects with respect to pregnancy, embryo-foetal development or early post-natal development.

An assessment of the risks and benefits should be performed by a health care professional before administering Supemtek to a pregnant woman.

Breast-feeding

It is not known whether Supemtek vaccine is excreted in human milk.

An assessment of the risks and benefits should be performed by a health care professional before administering Supemtek to a breast-feeding woman.

Fertility

No human fertility data are available.

The animal study with trivalent recombinant influenza vaccine did not indicate harmful effects on female fertility.

4.7 Effects on ability to drive and use machines

Supemtek has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

Summary of the safety profile

Supemtek has been administered to and safety data collected from 998 adults 18-49 years of age (Study 1) and 4328 adults 50 years of age and older (Study 2).

The most common reactions occurring after vaccine administration were injection-site reactions (tenderness and pain) reported overall by 48% and 37% of study participants 18-49 years of age receiving Supemtek respectively. In study participants 50 years of age and older, injection site tenderness was reported by 34% and injection site pain reported by 19%.

The severity of the reactions was mild to moderate. Onset usually occurred within the first 3 days after vaccination. All resolved without sequelae.

Tabulated list of adverse reactions

The adverse reactions are listed by MedDRA system organ class under headings of frequency using the following convention:

Very common (≥1/10);

Common (≥1/100 to <1/10);

Uncommon (≥1/1,000 to <1/100);

Rare (≥1/10,000 to <1/1,000);

Very rare (<1/10,000);

Frequency not known (adverse reactions from post-marketing experience; cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.

Table 1: Adverse reactions reported following vaccination in adults 18 years and older during clinical trials and post-marketing surveillance

MedDRA System Organ class

Very common

(≥1/10)

Common

(≥1/100 to <1/10)

Uncommon

(≥1/1,000 to <1/100)

Rare

(≥1/10,000, <1/1,000)

Frequency not known

Immune system disorders

Hypersensitivity including anaphylactic reaction

Nervous system disorders

Headache, Fatigue

Dizziness(4,6)

Guillain-Barré syndrome7

Respiratory, thoracic and mediastinal disorders

Cough,

Oropharyngeal pain

Gastrointestinal disorders

Nausea

Diarrhoea(4)

Skin and subcutaneous tissue disorders

Pruritus(2,4) , Dermatitis(4,5), Rash(4,5)

Urticaria(4,6)

Musculoskeletal and connective tissue disorders

Myalgia(1), Arthralgia(1)

General disorders and administration site conditions

Local tenderness,

Local pain

Firmness / Swelling, Redness, Fever (2,3), Shivering / Chills,

Flu-like symptoms(4,6), Injection site pruritus(4)

(1) Common in adults 50 years of age and older.

(2) Rare (≥1/10,000 to <1/1,000) in adults 50 years of age and older.

(3) ≥38.0°C (100.4°F).

(4) Reported as unsolicited adverse reaction.

(5) Not reported in adults 50 years of age and older.

(6) Not reported in adults 18-49 years of age.

(7) Reported from post-marketing surveillance, no causal relationship established.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Medicines and Healthcare products Regulatory Agency (MHRA), Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

No cases of overdose reported.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Influenza vaccine, ATC code: J07BB02

Immunogenicity

Supemtek was evaluated in healthy adults of 18-49 years of age in a randomized, observer-blind, active controlled, non-inferiority immunogenicity, multi-center trial conducted during the 2014-2015 influenza season in the United States (study 1).

In the study 1, subjects received Supemtek (N=998) or an egg-based quadrivalent inactivated influenza vaccine (IIV4) (N=332). Immunogenicity was assessed before and 28 days after administration of a single dose of study vaccine.

Haemagglutination inhibition (HAI) geometric mean titers (GMTs) were determined for the two vaccine groups for each vaccine antigen. Immunogenicity was compared by calculating the difference in seroconversion rates (SCR) and the ratios of GMTs of Comparator to Supemtek.

Study 1 had two co-primary endpoints: GMTs and Day 28 HAI seroconversion rates for each of the four antigens contained in the study vaccines.

Supemtek met the success criterion for GMTs for three of the four antigens but did not meet the success criteria for the B/Victoria lineage antigen (Table 2). Antibody titres against the B/Victoria were low in both vaccine groups.

Table 2: Comparison of Day 28 Post-Vaccination Geometric Mean Titers (GMT) for Supemtek and Comparator in Adults 18-49 Years of Age, Study 1 (Immunogenicity Population) 1,2,3

Antigen

Post-vaccination GMT Supemtek N=969

Post-vaccination GMT Comparator N=323

GMT Ratio Comparator/ Supemtek (95% CI)

A/H1N1

493

397

0.81 (0.71, 0.92)

A/H3N2

748

377

0.50 (0.44, 0.57)

B/Yamagata

156

134

0.86 ( 0.74, 0.99)

B/Victoria

43

64

1.49 (1.29, 1.71)

Abbreviations: CI, confidence interval; GMT, geometric mean titer.

1 HI titers were assayed using egg-derived antigens.

2 Comparator: egg-based quadrivalent inactivated influenza vaccine.

3 Success in meeting the GMTs endpoint was pre-defined as an upper bound (UB) of the two-sided 95% CI of GMTComparator / GMT Supemtek ≤ 1.5.

Supemtek met the success criterion for SCRs for three of the four antigens (Table 3), but not for the B/Victoria lineage. The HAI response to the B/Victoria lineage antigen was low in both vaccine groups.

Table 3: Comparison of Day 28 Seroconversion Rates for Supemtek and Comparator in Adults 18-49 Years of Age, Study 1 (Immunogenicity Population) 1,2,3,4

Antigen

SCR (%, 95% CI) Supemtek N=969

SCR (%, 95% CI) Comparator N=323

SCR Difference (%) Comparator - Supemtek [95% CI]

A/H1N1

66.7 (63.6, 69.6)

63.5 (58.0, 68.7)

-3.2 (-9.2, 2.8)

A/H3N2

72.1 (69.2, 74.9)

57.0 (51.4, 62.4)

-15.2 (-21.3, -9.1)

B/Yamagata

59.6 (56.5, 62.8)

60.4 (54.8, 65.7)

0.7 (-5.4, 6.9)

B/Victoria

40.6 (37.4, 43.7)

58.2 (52.6, 63.6)

17.6 (11.4, 23.9)

Abbreviations: CI, confidence interval; SCR, seroconversion rate

1 HI titers were assayed using egg-derived antigens.

2 Comparator was an egg-based quadrivalent inactivated influenza vaccine.

3 Seroconversion was defined as either a pre-vaccination HAI titer of <1:10 and a post-vaccination HAI titer of ≥1:40, or a pre-vaccination HAI titer of ≥1:10 and a minimum 4- fold rise in post vaccination HAI titer, at Day 28.

4 Success in meeting the seroconversion rate (SCR) endpoint was pre-defined as an upper bound (UB) of the two-sided 95% CI of SCR Comparator – SCR Supemtek ≤10%.

The study 1 in adults 18-49 years of age was conducted in parallel to the study 2 in adults of 50 years of age and older. These adults 18-49 years of age were vaccinated during the same influenza season (2014-2015 Northern Hemisphere influenza season) and received the same Supemtek formulation (same vaccine strain composition) as adults of 50 years of age and older in the study 2. The immune response induced by Supemtek was assessed by the same HAI assay and performed by the same laboratory for both studies. The immunogenicity results in adults 18-49 years of age (study 1) and adults 50 years of age and older (study 2) are presented in table 4.

Table 4: Summary of HAI Antibody Response to Supemtek for Each Strain in Adults 18-49 years (Study 1) and Adults≥50 years (Study 2) - Immunogenicity Analysis Set

Adults 18-49 years

N=969

Adults ≥50 years

N=314

GMT post-vaccination (95% CI)

A/California/7/2009 (H1N1)

493 (460; 527)

190 (164; 221)

A/Texas/50/2012 (H3N2)

748 (700; 800)

522(462; 589)

B/Massachusetts/02/2012 (Yamagata lineage)

156 (145; 168)

55 (48; 64)

B/Brisbane/60/2008 (Victoria lineage)

43 (40; 46)

29 (26; 33)

SCR % (95% CI)

A/California/7/2009 (H1N1)

66.7 (63.6; 69.6)

44.9 (39.3; 50.6)

A/Texas/50/2012 (H3N2)

72.1 (69.2; 74.9)

54.5 (48.8; 60.1)

B/Massachusetts/02/2012 (Yamagata lineage)

59.6 (56.5; 62.8)

38.9 (33.4; 44.5)

B/Brisbane/60/2008 (Victoria lineage)

40.6 (37.4; 43.7)

21.0 (16.6; 25.9)

GMTR % (95% CI)

A/California/7/2009 (H1N1)

8.35 (7.59; 9.19)

4.31 (3.71; 5.02)

A/Texas/50/2012 (H3N2)

10.1 (9.12; 11.1)

6.01 (5.03; 7.18)

B/Massachusetts/02/2012 (Yamagata lineage)

3.59 (3.35; 3.85)

2.16 (1.94; 2.40)

B/Brisbane/60/2008 (Victoria lineage)

5.89 (5.43; 6.40)

3.18 (2.81; 3.59)

N=number of subjects with available data for the considered endpoint

GMT: Geometric Mean Titer; CI: Confidence Interval; SCR: Seroconversion rate; GMTR: Geometric Mean Titer of individuals ratios (post dose / pre dose)

These immunogenicity data provide supportive information for the 18-49 years of age group in addition to vaccine efficacy data available in adults ≥ 50 years of age (see Clinical Efficacy).

Clinical efficacy

Supemtek efficacy in terms of prevention of laboratory-confirmed influenza-like illness (ILI) caused by any strain of influenza, was evaluated in adults ≥ 50 years of age and conducted during the 2014-2015 influenza season in the United States (study 2).

A total of 8963 healthy, medically stable adults were randomized in a 1:1 ratio to receive a single dose of Supemtek (n=4474) or an egg-based quadrivalent inactivated influenza vaccine (n=4489).

A total of 5412 (60.4%) subjects were 50-64 years of age, 2532 (28.2%) were 65-74 years of age and 1019 (11.4 %) were ≥ 75 years of age.

The primary efficacy endpoint of Study 2 was reverse transcriptase polymerase chain reaction (rtPCR)-positive, protocol-defined ILI due to any strain of influenza.

Laboratory-confirmed protocol defined ILI was defined as having at least one symptom in each of two categories of respiratory and systemic symptoms, which could include sore throat, cough, sputum production, wheezing and difficulty breathing, or systemic symptoms such as fever > 99°F (>37°C) , chills, fatigue, headache and myalgia, laboratory-confirmed by rtPCR.

US epidemiological data for the 2014-2015 influenza season indicated that Influenza A (H3N2) viruses predominated and that most influenza A/H3N2 viruses were antigenically dissimilar while A/H1N1 and B viruses were antigenically similar to vaccine antigens. Supemtek met the pre-specified success criterion for non-inferiority to the comparator pre-defined as a lower bound of the two sided 95% CI >-20%.

Of the 4474 participants exposed to Supemtek in a phase 3 active-controlled study (Study 2), a total of 1761 were 65 years or older. Although no differences in safety or efficacy were observed between older and younger participants, the number of patients aged 65 and over in this study was not sufficient to determine statistically whether this age group will respond differently from younger individuals.

Table 5: Relative Vaccine Efficacy (rVE) of Supemtek versus Comparator against Laboratory-Confirmed Influenza, Regardless of Antigenic Similarity to Vaccine Antigens, Adults 50 Years of Age and Older, Study 2 (Efficacy Population)1,2

Supemtek (N=4303)

Comparator (N=4301)

RR

rVE %

(95% CI)

n

Attack Rate % (n/N)

n

Attack Rate % (n/N)

All rtPCR-positive Influenza3

96

2.2

138

3.2

0.70

30 (105, 47)

All rtPCR-positive Influenza A3

73

1.7

114

2.7

0.64

36 (14, 53)

All rtPCR-positive Influenza B3

23

0.5

24

0.6

0.96

4 (-72, 46)

All Culture-confirmed Protocol-defined ILI3,4

58

1.3

101

2.3

0.57

43 (21, 59)

Abbreviations: rtPCR=reverse transcriptase polymerase chain reaction; Comparator= an egg-based quadrivalent inactivated influenza vaccine; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Supemtek/Attack Rate IIV4); rVE = [(1-RR) x 100].

1 Excluded subjects with protocol deviations that could adversely affect efficacy.

2 Primary Analysis. All cases of rtPCR-confirmed influenza are included.

3 Post hoc analyses. All cases of influenza A were A/H3N2. Cases of influenza B were not distinguished by lineage.

4 Culture of rtPCR-positive samples was performed in MDCK cells.

5 The lower bound (LB) of the 95% confidence interval met the pre-specified, exploratory criterion for superior relative vaccine efficacy, LB > 9%.

Efficacy of trivalent recombinant influenza vaccine (RIV3)

The efficacy of trivalent recombinant influenza vaccine (RIV3) is relevant to Supemtek because both vaccines are manufactured using the same process and have overlapping compositions.

The efficacy of trivalent recombinant influenza vaccine in protecting against influenza illness was evaluated in a randomized, observer-blind, placebo-controlled multicenter trial conducted in the United States during the 2007-2008 influenza season in adults 18-49 years of age (Study 3).

Study 3 enrolled and vaccinated 4648 healthy adults randomized in a 1:1 ratio to receive a single dose of RIV3 (n=2344) or saline placebo (n=2304).

The primary efficacy endpoint of Study 3 was defined as an influenza-like illness (ILI) with a positive culture for an influenza virus strain antigenically resembling a strain represented in RIV3. ILI is defined as fever of ≥100°F (37.8°C) oral accompanied by cough, sore throat, or both, on the same or consecutive days. Attack rates and vaccine efficacy (VE), defined as the reduction in the influenza rate for RIV3 relative to placebo, were calculated for the total vaccinated cohort (n=4648).

Due to very small number of cultured confirmed influenza cases with matched strains, an exploratory analysis of VE of RIV3 against all strains, regardless of antigenic match, isolated from any subject with an ILI, not necessarily meeting ILI criteria was done, demonstrated an efficacy estimate of 44.8% (95% CI 24.4, 60.0). See Table 6 for VE by case definition.

Table 6: Vaccine Efficacy Against Culture-Confirmed Influenza in Healthy Adults 18-49 Years of Age, Study 31,3

Case definition

RIV3 (N=2344)

Saline Placebo (N=2304)

RIV3 Vaccine Efficacy4 %

95% Confidence

Interval

Cases,

n

Rate, %

Cases,

n

Rate, %

Positive culture with a strain represented in the vaccine

CDC-ILI2, all matched strains5

1

0.04

4

0.2

75.4

(-148.0, 99.5)

Any ILI, all matched strains

2

0.1

6

0.3

67.2

(-83.2, 96.8)

Positive culture with any strain, regardless of match to the vaccine

CDC-ILI2, all strains

44

1.9

78

3.4

44.6

(18.8, 62.6)

Sub-Type A

26

1.1

56

2.4

54.4

(26.1, 72.5)

Type B

18

0.8

23

1.0

23.1

(-49.0, 60.9)

Any ILI, all strains

64

2.7

114

4.9

44.8

(24.4, 60.0)

Sub-Type A

41

1.7

79

3.4

49.0

(24.7, 65.9)

Type B

23

1.0

36

1.6

37.2

(-8.9, 64.5)

1 Vaccine efficacy (VE) = 1 minus the ratio of RIV3 /placebo infection rates (10).

2 Centers for Disease Control and Prevention - defined influenza-like illness (CDC-ILI) defined as fever of ≥100°F (37.8°C) oral accompanied by cough and/or sore throat, on the same day or on consecutive days.

3 The pre-defined success criterion for the primary efficacy analysis was that the lower bound of the 95% confidence interval (CI) of VE should be at least 40%.

4 Determined under the assumption of Poisson event rates, according to Breslow and Day, 1987.

5 Primary endpoint of trial.

Paediatric population

The European Medicines Agency has waived the obligation to submit the results of studies with Supemtek in children from 6 months to 3 years of age for the prevention of influenza infection.

The European Medicines Agency has deferred the obligation to submit the results of studies with

Supemtek in children from 3 years to 17 years of age for the prevention of influenza infection (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

Not applicable.

5.3 Preclinical safety data

Non-clinical safety data on the trivalent formulation revealed no special hazard for humans based on conventional studies of repeat dose and local toxicity, reproductive and developmental (including teratogenicity) toxicity and safety pharmacology studies.The results of these studies with trivalent recombinant influenza vaccine are relevant to Supemtek because both vaccines are manufactured using the same process and have overlapping compositions.

6. Pharmaceutical particulars
6.1 List of excipients

Polysorbate 20 (E432)

Sodium chloride

Sodium phosphate monobasic, monohydrate

Sodium phosphate dibasic, dodecahydrate

Water for injections

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

1 year.

6.4 Special precautions for storage

Store in a refrigerator (2°C - 8°C).

Do not freeze.

Keep the pre-filled syringe in the outer carton in order to protect from light.

6.5 Nature and contents of container

0.5 mL solution in a pre-filled syringe (Type I borosilicate glass) with plunger stopper (grey butyl rubber), with separate needle or without needle.

Pack size:

10 pre-filled syringes, with separate needle or without needle.

5 pre-filled syringes, with separate needle or without needle.

1 pre-filled syringe, with separate needle or without needle.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

The vaccine should be inspected visually for particulate matter and/or discoloration prior to administration. If either of these conditions exists, the vaccine should be discarded.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder

Aventis Pharma Limited

410 Thames Valley Park Drive

Reading

Berkshire

RG6 1PT

UK

Trading as:

Sanofi Pasteur

410 Thames Valley Park Drive

Reading

Berkshire

RG6 1PT

UK

8. Marketing authorisation number(s)

PLGB 04425/0879

9. Date of first authorisation/renewal of the authorisation

Date of first authorisation: 16 November 2020

Date of CAP conversion: 01 January 2021

10. Date of revision of the text

31 August 2021